Cytotoxic Cs in Immunodeficient Athymic Mice

References

• Flanagan S P. “Nude”, a new hairless gene with pleiotropic effects in mouse. Genet Re. (Camb) 1966; 8: 295–909
   PubMed Web of Science ®Google Scholar
• Pantelouris E M. Absence of a thymus in a mouse mutant. Nature 1968; 217: 370–371
   PubMed Web of Science ®Google Scholar
• Rygaard J, Povlsen C O. Heterotransplantation of a human malignant tumor to “nude” mice. Acta Path Microbiol Scand 1969; 77: 758–760
   PubMedGoogle Scholar
• Fodstad O. Transplantability of human tumors. The Nude Mouse in Oncology Research, E Boven, B Winograd. CRC Press, Boca Raton 1991; 65–80
   Google Scholar
• Herberman R B, Nunn M E, Lavrin D H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975; 16: 216–229
   PubMed Web of Science ®Google Scholar
• Herberman R B, Nunn M E, Lavrin D H. Natural cytotoxic reactivity of mouse lymohoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230–239
   PubMed Web of Science ®Google Scholar
• Lotzova E. Natural killer cells: Immunobiology and clinical prospects. Cancer Invest 1991; 9: 173–184
   PubMed Web of Science ®Google Scholar
• Stötter H, Lotze M T. Cytolytic effector cells against human tumors: distinguishing phenotype and function. Cancer Cells. 1990; 2: 44–55
   PubMedGoogle Scholar
• Pollack S B. Characteristics of mouse NK. cells and their precursors. Mechanisms of Cytotoxicity by NK, R B Herberman, D M Callewaert. Cells. Acad. Press Inc. 1985; 39–47
   Google Scholar
• Holden T H, Herberman R B, Santoni A, Nunn M E. Natural cell-mediated cytotoxicity in nude mice. Proceedings of the Symposium on The Use of Athymic (nude) Mice in Cancer Research, Columbus, Ohio. D P Houchens, A A Ovejera. Gustav Fisher, New York June 15-16, 1977; 81–92
   Google Scholar
• Radzikowski C, Rygaard J, Budzvnski W, Stenvang J F, Schou M, Vanasted A, Zenthen J. Strain-age dependent natural and activated in vitro cvtotoxicity in athymic nude mice. Submitted to Acta Pathol Microbiol Immunolog Scandinavica 1993
   Google Scholar
• Bean P, Aqah R, Mazumder A. Heterogeneity of cell surface structures involved in cytotoxicity mediated by lymphokine activated killer cells. J Biol Reso Modif 1990; 9: 92–97
   PubMedGoogle Scholar
• Gtönbera A, Erilsson E, Sinangi L F, Rnnholm M, Felzi T, Minden P, Klessling R. Comparison between murine natural antibodies and natural killer cells: Recognition of separate target structure as revealed by differential in vitro expression and dependence on glycosylation. JNCI 1985; 74(1)67–75
   PubMedGoogle Scholar
• Hanna N, Fidler I J. Expression of metastatic potential of allogeneic and xenoqeneic neoplasms in younq nude mice. Cancer Res 1981; 41: 438–444
   PubMed Web of Science ®Google Scholar
• Kozlowshi J M, Fidler I J, Camobell D, Xu Z L, Kaighn M E, Han I R. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984; 44: 3922–3529
   Google Scholar
• Zietman A L, Sugiyama E, Ramsav J R, Silobrcic V, Yeh E TH, Sedlacel R S, Suit H D. A comoarative study on the xenotransplantability of human solid tumors into mice with different genetic immune deficiencies. Int J Cancer 1991; 47: 755–759
   PubMedGoogle Scholar
• Radzikowski C, Vangsted A, Zeuthen J. Differential expression of cell membrane antigens, cytotoxic sensitivity, and tumorigenicity in athymic nude mice of a human urothelial cell line (HCV-29) and its v-raf-transfected variants. Contributions to Oncoloqy, H Huber, W Queißer, H H Fiebig, D P Berger. Immunodeficient Mice in Oncology, Karger, Basel 1992; Vol. 42: 231–245
   Google Scholar
• Budzynski W, Chirigos M, Gruys E. Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2. Cancer Iimmunol Immunother 1987; 24: 253–258
   PubMedGoogle Scholar
• Saito T, Weiss A, Miller J, Norcross M A, Germain R N. Specific antigen-Ia activation of transfected human T cell expressing murine T1 human T3 receptor complexes. Nature 1987; 325: 125–130
   PubMed Web of Science ®Google Scholar
• Bluestone J A, Cron R Q, Cotterman M, Houlden B A, Matis L A. Structure and specificity of T cell receptor on Major histocompatibility complex antigen-specific CD39±, CD4−-, CD8 T lymphocytes. J Exp Med 1988; 168: 1899–1916
   PubMedGoogle Scholar
• Brenner M B, Strominger J L, Krangel M S. The T cell receptor. Adv Immunol 1988; 43: 335–192
   Google Scholar
• MacDonald H R. Phenotypic and functional characteristics of “T-like” cells in nude mice. Exp Cell Biol 1984; 2–6
   PubMedGoogle Scholar
• MacDonald H R, Blanc C, Lees R K, Sordat B. Development of T-dependent immune function in nude mice. Immune-deficient Animals in Biomedical Research, J Rygaard, N Erünner, N Graem, Spang M Tomsen. Karger, Basel 1987; 51–58
   Google Scholar
• Kennedy J D, Pierce C W, Lake J P. Extrathymic T cell maturation. Phenotypic analysis of T cell subsets in nude mice as a function of age. J Immunology 1992; 148: 1620–1629
   PubMedGoogle Scholar
• Habu S, Shimamura K, Kumagai Y, Okumura K, Tamaoki N. Characterization of precursors a± allaspecific cytotoxic cells in nude mice. Immune-deficient Animals in Biomedical Research, J Rygaard, N Brunner, N Graem, Spang M Tomsen. Karger, Basel 1987; 82–84
   Google Scholar
• Ikehara S, Yasumizu R, Naliamcira T, Sekita K, Muso E, Ohtsuki H, Ogura M, Toki J, Inoue N, Sugiura K, Iwai H, Shintaku M, Ihara N, Hamashima J, Good R A. Role of thymus and the stem cells in the differentiation of T cells. Immune-deficient Animals in Biomedical Research, J Rygaard, N Brünner, N Graem, Spang M Tomsen. Karger, Basel 1987; 69–75
   Google Scholar
• Yoshikai Y, Matsuzaki G, Inoue T, Nomoto K. An increase in number of T-cell receptor bearing T cells in athymic nude mice treated with camplete Freunds adjuvants. Immunology 1990; 70: 61–65
   PubMedGoogle Scholar
• Lake J F, Pierce C W, Kennedy J D. T cell receptor expression by T cells that mature extrathymically in nude mice. Cellular Immunol 1991; 135: 259–265
   PubMedGoogle Scholar
• Miller R G, Benveniste P, Reimann J. Preferential development of bearing T cells in athymic nude bone marrow. Curr Top Microbiol Immunol 1991; 173: 29–32
   PubMedGoogle Scholar
• Borst J, Vroom T M, Bos J D, Van Dongen J JM. Tissue distribution and repertoire selection of human T cells: Comparison with the murine system. Curr Top Microbiol Immunol 1991; 173: 41–46
   PubMedGoogle Scholar
• O'Brien R L, Born W. Specificity of mycobacteria self-reactive gamma-delta cells. Current Top Microbiol Immunol 1991; 173: 143
   PubMedGoogle Scholar
• Ericsson P O, Hansson J, Widegren B, Dohlsten M, Sjögren H O, Hedlund G. In vivo induction of T cells with hiqhly potent and selective anti-tumor cytotoxicity. Eur J Immunol 1991; 21: 2797–2802
   PubMed Web of Science ®Google Scholar
• Marincola F M, Drucker B J, Siao D Y, Hough K L, Holder W D. The nude mouse as a model for the study of human pancreatic cancer. J Surg Res 1989; 47: 520–529
   PubMed Web of Science ®Google Scholar
• Yoshino I, Kimura G, Matzuzaki G, Nomoto K. T lymphocytes bearing γ/type T-cell receptor in thymic tumor tissues. JNCI 1992; 84(22)1755–1756
   PubMedGoogle Scholar
• Hamilton T A, Adams D O. Mechanisms of macrophage-mediated injury. Tumor Immunoloqy. Mechanisms, Diagnosis, Therapy, Den W Otter, E J Ruitenberg. Elsevier, Amsterdam 1987; 89–108
   Google Scholar
• Nelson D S. Alterations in macrophage function in tumor bearina hosts. Immune Responses to Metastases, R B Herberman, R H Wiltrout, E Gorelil. CRC Press Inc, Boca Raton 1987; Vol. I.: 79
   Google Scholar
• Oehler J R, Herberman R F, Holden H T. Modulation of immunity by macrophages. Pharmacol Ther (A) 1978; 2: 551–560
   Web of Science ®Google Scholar
• Holub M, Vetvicka V, Fornusek L, Paluska E. Phagocytic cells of athymic nude mice in fetal life. Immune-deficient Animals in Biomedical Research, J Rygaard, N Frünner, N Graem, M Spang-Thomsen. Karger, Basel 1987; 59–68
   Google Scholar
• Sharp A K, Colston M J. The regulation of macrophage activity in congenitally athymic mice. Eur J Immunol 1984; 14: 102–105
   PubMed Web of Science ®Google Scholar
• Benomar A, Gerlier D, Dore J F. Natural resistance to xenografts of human melanoma cell lines in nude mice. Relation with macrophage activation. Immune-deficient Animals in Biomedical Research, J Rygaard, N Brünner, N Graem, Thomsen M Spang. Karger, Basel 1987; 104–107
   Google Scholar
• Levy M H, Wheelock E F. Effects of intravenous sillca on immune and non-immune functions of the murine host. J Immunol 1975; 115: 41–48
   PubMedGoogle Scholar
• Hopper D G, Pimm M V, Baldwin R W. Silica abrogation of mycobacterial adjuvant contact Suppression of tumor in rats and athymic mice. Cancer Immunol Immunother 1976; 1: 147–144
   Google Scholar
• Kopper L, van Hanh T, Lapis K, Timar J. Increased take rate of human tumour xenografts after carrageenan treatment. Eur J Cancer 1980; 16: 671–678
   Google Scholar
• Thomson A W, Fowler E F. Potentation of: tumour growth by carrageenan. Transplantation 1977; 24: 397–400
   PubMed Web of Science ®Google Scholar
• Kopper L, van Hanh T, Hegedus C, Laois C. Growth of human colorectal tumor xenografts in immunosuppressed mice reconstituted with normal cells. Exp Cell Biol 1981; 49: 141–147
   PubMedGoogle Scholar
• Quan P C, Kolb J F, Lespinats G. NK activity in carrageenan-treated mice. Immunology 1980; 40: 495–503
   PubMed Web of Science ®Google Scholar
• Stutman O, Lattime E C, Figarella E F. Natural cytotoxic cells against solid tumors in mice. A camparison with natural killer cells. Fed Proc 1981; 40: 2699–2704
   PubMedGoogle Scholar
• Eubenik J. Tumor inhibitory effects of regional interleukin-2 administration and the role of lymphokine-activated killer cells. Interleukin-2 and Killer Cells in Cancer, E Lotzowa, R B Herberman. CRC Press Inc, Boca Raton, Florida 1991; 235–244
   Google Scholar
• Mule J J, Rosenberq S A. Successful adoptive immunotherapy of established metastases with lymohokine activated killer cells and recombinant interleukin-2. Immune Response to Metastases, R B Herberman, R H Wiltrout, E Gorelik. CRC Press Inc, Boca Raton, Florida 1987; 2: 69–94
   Google Scholar
• Rosenberg S A, Mule J J, Gpiess P J., et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2. J Exp Med 1985; 161: 1169–1188
   PubMed Web of Science ®Google Scholar
• Papa M L, Mule J J, Rosenberg S A. Antitumor efficacy of Iymahokine activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and non-immunoyenic murine tumors of three distinct histological types. Cancer Res 1986; 46: 4973–4978
   PubMed Web of Science ®Google Scholar
• Kolitz J E, Mertelsmann R. The immunotherapy of human cancer with interleukin-2: present status and future directions. Cancer Invest 1991; 9: 529–542
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf I GH, Negrin R S, Kiem H S, Blume K G, Weissman I L. Use of a SCID mouse/human lymohoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139–149
   PubMed Web of Science ®Google Scholar
• Hermann G, Zeuthen J, Claesson M H. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: Cytotoxicity, target recognition and phenotype of: effector cells lysing the Daudi T24, and K562 tumor cell lines. Nat Immun 1992; 11: 7–16
   PubMedGoogle Scholar
• Ortaldo J R, Mason A, Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 1986; 164: 1193–1205
   PubMed Web of Science ®Google Scholar
• Kalland T, Belfrage H, Bhiladvala P, Hedlung G. Analysis of the murine lymohokine-activated killer (LAK) cell phenomenon:dissection of effectors and progenitors into NK- and T-like cells. J Immunol 1987; 138: 3640–3645
   PubMedGoogle Scholar
• Merluzzi V J, Smith M D, Last-Barney K. Similarities and distinctions between murine natural killer cells and lymphokine-activated killer cells. Cellular Immunol 1986; 100: 563–569
   PubMed Web of Science ®Google Scholar
• Andriole G L, Mule J J, Hansen C T, Linehan W, Rosenberg S A. Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on analysis of congenitally immunodeficient mice. J Immunol 1985; 135: 2911–2913
   PubMed Web of Science ®Google Scholar
• Hoskin D W, Stankova J, Anderson S K, Roder J C. A functional and ahenotypic comparison of murine natural killer (NK) cells and lymohokine-activated killer (LAK) cells. Int J Cancer 1989; 43: 940–948
   PubMed Web of Science ®Google Scholar
• Campos-Perera C, Murgita H A, Hauptman S P, Gronvik K O. Identification of macromalecular insoluble cold globulin (MICG) as a new marker shared by NK and ADCC cells but not expressed by NC cells. Immunology 1986; 59: 101–107
   PubMedGoogle Scholar
• Lauzon R J, Siminovitch K A, Roder J C. T-cell receptor-gene rearrangements in cells with natural killer activity in the mouse. Immunol Hes 1986; 5: 191–200
   Google Scholar
• Ortaldo J R, Porter H R, Miller P, Stevenson H C, Ozols R F, Hamilton T C. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. Cancer Res 1986; 46: 4414–4419
   PubMed Web of Science ®Google Scholar
• Bubenik J, Lotzova E, Zeuthen J, Bubenikova D, Simova J, Indrova M. Gene therapy of cancer: use of inter leukin-2 (IL-2) gene transfer in local immunotherapy. J Exp Clin Canc Res 1991; 10: 213–220
   Google Scholar
• Bubenik J, Voitenok N N, Kieler J, Prassolov V S, Chumakov P M, Bubenikowa D, Simova J, Jandlova T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Letters 1988; 19: 279–282
   PubMed Web of Science ®Google Scholar
• Thistlethwaite J R, Cosimi A B, Delmonico F L. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 1984; 38: 695–701
   PubMed Web of Science ®Google Scholar
• Stankova J, Hoskin D W, Roder J C. Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK populations. Gellular Immunol 1989; 121: 13–29
   Google Scholar
• Hoskin D W, Stankova J, Anderson S K, Roder J C. Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies. Cancer Immunol Immunother 1989; 29: 226–230
   PubMedGoogle Scholar
• Yang S C, Fry K D, Grimm E A, Roth J A. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1755 melanoma metastases followinq anti-CD3, interleukin-2, and tumor necrosis factor-alfa combination immunotharapy. J Immunother 1991; 10: 326–335
   PubMedGoogle Scholar
• Payer A, Strohal R, Kutil R, Elbe A, Stingl G. Demonstration of a CD3 lymphocyte subset in the epidermis of athymic nude mice. Evidence for T cell receptor diversity. J Immunol 1992; 149: 413–420
   PubMedGoogle Scholar
• Kikly K, Dennert G. Evidence for extrathymic development of TNK cells NK1± CD3 cells responsible for acute marrow graft rejection are present in deficient mice. J Immunol 1992; 149: 403–412
   PubMedGoogle Scholar
• Creagan E. Biological response modifiers. Current Hematology and Oncology, V F Fairbanks. Year Book Medical Publishers Inc. 1980; 6: 27–58
   Google Scholar
• Malik S TA, Halkwill F R. Cytokines. The Nude Mouse in Oncology Research, E Baven, H Winograd. CRC Press Inc, Boca Raton 1991; 247–261
   Google Scholar
• Balkwill F R. Animal models for investigating antitumor effect of interferon. Meth Enzymol 1986; 119: 649–657
   PubMedGoogle Scholar
• Kelly S A, Gschmeissner S, East N, Balkwill F R. Enhancement of metastatic potential by γ-interferon. Cancer Res 1991; 51: 4020–4027
   PubMedGoogle Scholar
• Beutler H, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584–588
   PubMed Web of Science ®Google Scholar
• Degliantoni G, Murphy M, Kobayashi M, Francis M K, Perussia B, Trinchieri G. NK cell derived hematopoietic colony inhibiting activity and NK cytotoxic factor, relationship with tumor necrosis factor and synergism with immune interferon. J Exp Med 1985; 162: 1512–1530
   PubMed Web of Science ®Google Scholar
• Hahnson R R, Ratliff T L. In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). J Urol 1990; 144: 172–175
   PubMedGoogle Scholar
• Van de Wiel P, Bloksma N, Kuper C F, Hofhuis F M, Willers J M. Macroscopic and microscopic early effects of tumor necrosis factor on murine meth A sarcoma and relation to curative activity. J Pathol 1989; 157: 65–73
   PubMedGoogle Scholar
• Ostensen M E, Thiele D L, Lipsky F E. Tumor necrosis factor-α enhances cytolytic activity of human natural killer cells. J Immunol 1987; 138: 4185–4191
   PubMed Web of Science ®Google Scholar
• Philip R, Epstein L B. Tumor necrosis factor as an immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ interferon and interleukin-1. Nature 1986; 323: 86–89
   PubMed Web of Science ®Google Scholar
• Shalaby M R, Aggarwal B B, Rinderknecht L P, Syedersky B S, Palladino M A. Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factor. J Immunol 1985; 135: 2069–2073
   PubMed Web of Science ®Google Scholar
• Brokmeyer H E, Williams D E, Lu L, Cooper S, Anderson S L, Beyer G S, Hoffman R, Rubin B Y. The suppressive influence of human tumor necrosis on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-γ. J Immunol 1986; 136: 4487–4495
   PubMedGoogle Scholar
• Rubin S C, Hoskins W J, Markman M, Feferici M, Lloyd K O, Lewis J L. Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer. Gynecol Oncol 1989; 34: 353–356
   PubMedGoogle Scholar
• Manetta A, Podczaski E, Zaino R J, Satyaswaroop P G. Therapeutic effect of recombinant human tumor necrosis factor in ovarian carcinoma xenografts in nude mice. Gynecol Oncol 1989; 34: 360–364
   PubMedGoogle Scholar
• Ralkwill F R, Lee A, Adlam G, Moodie E, Thomas A, Tavernier J, Fiers W. Human turnour xenografts treated with tumor necrosis factor alone or in combinations with interferons. Cancer Res 1986; 46: 3990–3993
   PubMedGoogle Scholar
• Nio Y, Shiraishi T, Tsubano M, Morimoto H, Tseng C C, Kawabata K, Masai Y, Tun T., Fukumoto M, Tobe T. In vivo effect of human recombinant tumor necrosis factor alone and in combination with other biological response modifiers on human digestive organ cancer xenografts transalanted in nude mice. Biotherapy 1991; 3: 337–344
   PubMedGoogle Scholar
• Murro M, Namoto Y, Orita K. Mechanism of the combined antitumor effect of natural human tumor necrosis factor alfa and natural human interferon alfa on cell cycle progression. Jpn J Cancer Res 1991; 82: 118–126
   PubMedGoogle Scholar
• Haranaka K, Satomi N, Sahurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumours and heterotransplanted human tumours in nude mice. Int J Cancer 1984; 34: 263–267
   PubMed Web of Science ®Google Scholar